In a new commentary for Pharmaceutical Market Europe, Precision for Value’s Austin Speier, VP, Emerging Technology, examines the promise and advantages of integrating digital biomarkers into precision medicine. (more…)
In an in-depth commentary for Pharmaceutical Market Europe, senior economist Jason Shafrin argues for real-world evidence (RWE) to become the “gold standard” of scientific evidence and heath technology assessments. (more…)
Jeremy Schafer, director of Precision’s Payer Access Solutions, contributes his perspectives on drug pricing in a PharmaVOICE feature article. (more…)
Precision Xtract is proud to be named one of the year’s most innovative developments by industry insider PM360. (more…)
A new Precision Health Economics-authored study on the societal value of CAR-T therapy is generating a significant level of interest within the scientific community. (more…)
Precisioneffect Chief Creative Officer Deborah Lotterman pens a new commentary in the latest edition of MedAd News, “Making Sense of the Irrational.” (more…)
Senior Vice President Jeremy Schafer and Chief Creative Officer Deborah Lotterman submit a new commentary to MedAd News,“Enriching the Patient Journey: When Cost Creates Side Effects.” (more…)
In the latest edition of Managed Care, Precision for Value Payer Strategy Team members Ami Gopalan and Jeremy Schafer take a look at some of the cost-sharing strategies being employed by PBMs and ask the question, What latent effects might these programs have? (more…)
In the latest edition of Clinical Leader, Precision for Value’s Dominic Galante addresses how real-world evidence is being leveraged after the adoption of the 21st Century Cures Act, and provides some next steps for life science companies. (more…)
MM&M editor-in-chief Marc Iskowitz quotes Precision’s Maureen Hennessey and cites new findings from Precision for Value’s Rapid Pulse survey in an article examining Otsuka’s new “digital drug” and the continued importance of adherence. (more…)